TPI To Host First Quarter Fiscal Year 2012 Earnings Conference Call On Monday, November 14, 2011 At 8:30 A.m. ET

CHENGDU, China, Nov. 7, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the first quarter of fiscal year 2012 ending September 30, 2011 will be held at 8:30 a.m. Eastern Time on Monday, November 14, 2011.

Interested parties may access the call by dialing 1-888-846-5003 (toll-free) or 1-480-629-9856 (International).

The conference ID is 4486385. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling 1-877-870-5176 (toll-free) or 1-858-384-5517 (International), from November 14, 2011 at 11:30 am Eastern Time to November 28, 2011 at 11:59 pm Eastern Time. Replay pin number: 4486385.

This call is being web cast by ViaVid Broadcasting and can be accessed at the following link: http://viavid.net/dce.aspx?sid=00008F90

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.

For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

1 2 Next › Last »